Chronic Lymphocytic Leukaemia (CLL) is the most common adult blood cancer in the western world, and it predominantly affects older adults. Most people are diagnosed after the age of 70, but increasing ...

Pirtobrutinib demonstrated efficacy in MCL and CLL/SLL, with over 70% of MCL and 80% of CLL/SLL patients reporting stable or improved symptoms. The BRUIN phase 1/2 study highlighted significant ...

Physical activity significantly improves quality of life and reduces symptom burden in CLL patients, yet only 24.6% meet recommended activity levels. Treatment-naïve patients are more likely to meet ...

Personalised exercise guidance is needed for people living with Chronic Lymphocytic Leukaemia (CLL), the most common type of blood cancer, according to a new study led by the University of Surrey. The ...

CLL," Cleveland Clinic hematologist/oncologist Allison Winter, MD, and host John Mangels explore how clinicians can communicate effectively and empathetically with patients navigating a chronic ...

Current and emerging treatments for relapsed or refractory CLL show promise, with outcomes expected to improve beyond current data. Treatment responses in CLL can last for years, especially in ...

In "Beyond Diagnosis: CLL," Cleveland Clinic hematologist/oncologist Allison Winter, MD, and host John Mangels explore how clinicians can communicate effectively and ...